This Biotech Stock Could Launch Its First CRISPR Drug In 2022 [Investor's Business Daily]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Investors Business Daily
Related news Crispr Therapeutics ( CRSP ) will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage of Crispr stock with a buy rating. Three biotech stocks are developing therapies using CRISPR gene editing : Crispr Therapeutics, Intellia Therapeutics ( NTLA ) and Editas Medicine ( EDIT ). These companies believe they can use gene editing to remove or change faulty disease-causing genes. Needham analyst Alan Carr initiated coverage of Crispr stock with a buy rating and a 22 price target. Crispr Therapeutics has the rights to the gene-editing technology from Emmanuelle Charpentier, who played a central role in developing the technique. "Crispr is initially focused on ex vivo (outside the body) applications of the technology, which we believe are associated with reduced technical and safety risks and yet still hold substantial value, particularly in immuno-oncology," he said in a note to clients. The company's most advanced gene-editin
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target raised by analysts at Citigroup Inc. from $88.00 to $89.00. They now have a "buy" rating on the stock.MarketBeat
- Bullish Trendline Has Never Failed Crispr Therapeutics Stock [Yahoo! Finance]Yahoo! Finance
- Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- bluebird (BLUE) Underperforms Industry YTD Amid Challenges [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/10/24 - Form SC
- CRSP's page on the SEC website